Novel therapies for malignant pleural effusion: Antiangiogenic therapy and immunotherapy (Review).
Int J Oncol
; 58(3): 359-370, 2021 03.
Article
em En
| MEDLINE
| ID: mdl-33650668
ABSTRACT
Patients with a variety of malignancies can develop malignant pleural effusion (MPE). MPE can cause significant symptoms and result in a marked decrease in quality of life and a poor prognosis. MPE is primarily considered as an immune and vascular manifestation of pleural metastases. In the present review, the existing evidence supporting the applicability of antiangiogenic therapy and immunotherapy for the treatment of MPE was summarized. Patients with MPE have benefited from antiangiogenic agents, including bevacizumab and endostar; however, no relevant prospective phase III trial has, thus far, specifically analyzed the benefit of antiangiogenic therapy in MPE. Immunotherapy for MPE may be sufficient to turn a dire clinical situation into a therapeutic advantage. Similar to antiangiogenic therapy, more clinical data on the efficiency and safety of immunotherapy for controlling MPE are urgently required. The combined use of antiangiogenic therapy and immunotherapy may be a promising strategy for MPE, which requires to be further understood.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
6_ODS3_enfermedades_notrasmisibles
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Derrame Pleural Maligno
/
Inibidores da Angiogênese
/
Terapia Viral Oncolítica
/
Imunoterapia
Tipo de estudo:
Prognostic_studies
Aspecto:
Patient_preference
Limite:
Humans
Idioma:
En
Revista:
Int J Oncol
Ano de publicação:
2021
Tipo de documento:
Article